Oyler says the CDK4 inhibitor and B7-H4 ADC went from first-in-human to pivotal in 2.5 years, showing the speed of BeOne's global development model.
Both moved from first in human to pivotal development in just two and a half years, allowing us to rapidly close the gap with the competition. Now we are seeing that pipeline advance into registrational trials, which puts BeOne in an exceptionally select group of oncology innovators.
All statements by John Oyler ›
Oyler says BeOne is the only company with potentially best-in-class drugs across all three key mechanisms in B-cell malignancies, giving it a unique competitive position.
With BRUKINSA, BEQALZI, and tacabrutideg, we are the only company with potentially best-in-class medicines across the three key mechanisms of action in B-cell malignancies. So whether a patient wants continuous or fixed-duration therapy, or requires an option after progression, we will be able to meet the need with the right medicine, alone or in combination. No other company is positioned to do that.
Oyler argues BeOne's solid tumor pipeline is unusually productive, with five late-stage programs advancing toward registration at about the same time.
Most companies have just one exciting asset. Some have two. From just the first wave of our solid tumor pipeline, we have five, all advancing towards registration-enabling development in roughly the same time.
Oyler says BeOne's four competitive advantages form a compounding loop and the company will keep investing behind it to build the world's leading oncology company.
These advantages create a self-reinforcing feedback loop. Together, they enable us to drive industry-leading R&D returns at scale, turn that innovation into profitable growth, and to fund a growing level of investment in next-generation medicines. Each turn of the cycle strengthens the next.